In LN18 cells, PAD3 inhibitor led to a significant reduction in PHB levels, correlating with previous findings that Cl-amidine (pan-PAD inhibitor with most specificity for PAD3) affected PHB levels in this GBM cell line [9]. This evidence concerns the gene PHB1 and glioblastoma.